Review
Nature Reviews Immunology 7, 790-802 (October 2007) | doi:10.1038/nri2173
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
Paul J. Tacken1, I. Jolanda M. de Vries1, Ruurd Torensma1 & Carl G. Figdor1 About the authors
Abstract
The realization that dendritic cells (DCs) orchestrate innate and adaptive immune responses has stimulated research on harnessing DCs to create more effective vaccines. Early clinical trials exploring autologous DCs that were loaded with antigens ex vivo to induce T-cell responses have provided proof of principle. Here, we discuss how direct targeting of antigens to DC surface receptors in vivo might replace laborious and expensive ex vivo culturing, and facilitate large-scale application of DC-based vaccination therapies.
- View At a Glance
Author affiliations
- Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Tumour Immunology, Postbox 9101, Nijmegen, 6500HB, Netherlands.
Correspondence to: Carl G. Figdor1 Email: c.figdor@ncmls.ru.nl
